Business
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential $10 million near-term milestone payments and is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales THE WOODLANDS, Texas, March 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and Novo Nordisk A/S t
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Lexicon Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Lexicon Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/4d6e4fe42ab02751f185e7d242d7f8e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cpcXdPITJqolET8.Vg1gcg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYz/https://media.zenfs.com/en/globenewswire.com/4d6e4fe42ab02751f185e7d242d7f8e8","width":166,"height":50}},"lazy":false},{"type":"text","content":"LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders","length":151,"tagName":"p"},{"type":"text","content":"Lexicon has earned a second of three potential $10 million near-term milestone payments and is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales","length":223,"tagName":"p"},{"type":"text","content":"THE WOODLANDS, Texas, March 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and Novo Nordisk A/S today announced that Novo Nordisk has initiated a Phase 1 study with LX9851, a first-in-class, oral non-incretin development candidate.","length":258,"tagName":"p"},{"type":"text","content":"In March 2025, Lexicon signed an exclusive license agreement with Novo Nordisk for LX9851 in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications.","length":293,"tagName":"p"},{"type":"text","content":"Lexicon has earned a second $10 million milestone payment in 2026 from Novo Nordisk following initial dosing requirements in the Phase 1 study and is eligible for a third $10 million milestone payment that may be achieved later this year. In total, Lexicon is eligible to receive up to $1 billion in upfront and potential development, regulatory and sales milestone payments. Lexicon is also entitled to tiered royalties on net sales of LX9851.","length":444,"tagName":"p"},{"type":"text","content":"“We are thrilled with the progress of the Novo Nordisk team on initiating the clinical development of LX9851,” said Mike Exton, CEO and director of Lexicon. “The talented team at Novo N...